Carcinoid Lung Tumors Questions & Answers

1. Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA. Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg. 1985 Jun. 89 (6):819-25. [QxMD MEDLINE Link].

2. Meade RH. Tumors and cysts of the lung. A History of Thoracic Surgery. Springfield, IL: Charles C Thomas; 1961. 175-222.

3. Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics. 2006 Jan-Feb. 26 (1):41-57; discussion 57-8. [QxMD MEDLINE Link].

4. Han B, Sun JM, Ahn JS, Park K, Ahn MJ. Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute. Med Oncol. 2013 Mar. 30 (1):479. [QxMD MEDLINE Link].

5. Zhong CX, Yao F, Zhao H, Shi JX, Fan LM. Long-term outcomes of surgical treatment for pulmonary carcinoid tumors: 20 years' experience with 131 patients. Chin Med J (Engl). 2012 Sep. 125 (17):3022-6. [QxMD MEDLINE Link].

6. Cardillo G, Sera F, Di Martino M, Graziano P, Giunti R, Carbone L, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg. 2004 May. 77 (5):1781-5. [QxMD MEDLINE Link].

7. Cao C, Yan TD, Kennedy C, Hendel N, Bannon PG, McCaughan BC. Bronchopulmonary carcinoid tumors: long-term outcomes after resection. Ann Thorac Surg. 2011 Feb. 91 (2):339-43. [QxMD MEDLINE Link].

8. Chughtai TS, Morin JE, Sheiner NM, Wilson JA, Mulder DS. Bronchial carcinoid--twenty years' experience defines a selective surgical approach. Surgery. 1997 Oct. 122 (4):801-8. [QxMD MEDLINE Link].

9. Cote ML, Wenzlaff AS, Philip PA, Schwartz AG. Secondary cancers after a lung carcinoid primary: a population-based analysis. Lung Cancer. 2006 Jun. 52 (3):273-9. [QxMD MEDLINE Link].

10. Ducrocq X, Thomas P, Massard G. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg. 1998. 65:1410-4. [QxMD MEDLINE Link].

11. Harpole DH Jr, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg. 1992 Jul. 54 (1):50-4; discussion 54-5. [QxMD MEDLINE Link].

12. Rea F, Binda R, Spreafico G, Calabrò F, Bonavina L, Cipriani A, et al. Bronchial carcinoids: a review of 60 patients. Ann Thorac Surg. 1989 Mar. 47 (3):412-4. [QxMD MEDLINE Link].

13. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg. 1996 Sep. 62 (3):798-809; discussion 809-10. [QxMD MEDLINE Link].

14. Meisinger QC, Klein JS, Butnor KJ, Gentchos G, Leavitt BJ. CT features of peripheral pulmonary carcinoid tumors. AJR Am J Roentgenol. 2011 Nov. 197 (5):1073-80. [QxMD MEDLINE Link].

15. Gückel C, Schnabel K, Deimling M, Steinbrich W. Solitary pulmonary nodules: MR evaluation of enhancement patterns with contrast-enhanced dynamic snapshot gradient-echo imaging. Radiology. 1996 Sep. 200 (3):681-6. [QxMD MEDLINE Link].

16. Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging. 2011 Jun 15. 11:70-5. [QxMD MEDLINE Link].

17. Lococo F, Perotti G, Cardillo G, De Waure C, Filice A, Graziano P, et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. Clin Nucl Med. 2015 Mar. 40 (3):e183-9. [QxMD MEDLINE Link].

18. Hindié E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017. 7 (5):1159-1163. [QxMD MEDLINE Link]. [Full Text].

19. Esfahani AF, Chavoshi M, Noorani MH, Saghari M, Eftekhari M, Beiki D, et al. Successful application of technetium-99m-labeled octreotide acetate scintigraphy in the detection of ectopic adrenocorticotropin-producing bronchial carcinoid lung tumor: a case report. J Med Case Rep. 2010 Oct 18. 4:323. [QxMD MEDLINE Link]. [Full Text].

20. Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R, Maecke HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006 Oct. 33 (10):1123-33. [QxMD MEDLINE Link].

21. Musi M, Carbone RG, Bertocchi C, Cantalupi DP, Michetti G, Pugliese C, et al. Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy. Lung Cancer. 1998 Nov. 22 (2):97-102. [QxMD MEDLINE Link].

22. Dardick I, Christensen H, Stratis M. Immunoelectron microscopy for chromogranin A in small cell neuroendocrine carcinoma of lung. Ultrastruct Pathol. 1996 Jul-Aug. 20 (4):361-8. [QxMD MEDLINE Link].

23. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991 Jun. 15 (6):529-53. [QxMD MEDLINE Link].

24. Vitolo D, Ciocci L, Deriu G, Spinelli S, Cortese S, Masuelli L, et al. Laminin alpha2 chain-positive vessels and epidermal growth factor in lung neuroendocrine carcinoma: a model of a novel cooperative role of laminin-2 and epidermal growth factor in vessel neoplastic invasion and metastasis. Am J Pathol. 2006 Mar. 168 (3):991-1003. [QxMD MEDLINE Link].

25. Warren WH, Memoli VA, Gould VE. Immunohistochemical and ultrastructural analysis of bronchopulmonary neuroendocrine neoplasms. I. Carcinoids. Ultrastruct Pathol. 1984. 6 (1):15-27. [QxMD MEDLINE Link].

26. Warren WH, Memoli VA, Gould VE. Immunohistochemical and ultrastructural analysis of bronchopulmonary neuroendocrine neoplasms. II. Well-differentiated neuroendocrine carcinomas. Ultrastruct Pathol. 1984. 7 (2-3):185-99. [QxMD MEDLINE Link].

27. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972 Sep. 64 (3):413-21. [QxMD MEDLINE Link].

28. Ha SY, Lee JJ, Cho J, Hyeon J, Han J, Kim HK. Lung parenchymal invasion in pulmonary carcinoid tumor: an important histologic feature suggesting the diagnosis of atypical carcinoid and poor prognosis. Lung Cancer. 2013 May. 80 (2):146-52. [QxMD MEDLINE Link].

29. Yao JC, Fazio N, Singh S, et al, RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5. 387 (10022):968-977. [QxMD MEDLINE Link].

30. Yendamuri S, Gold D, Jayaprakash V, Dexter E, Nwogu C, Demmy T. Is sublobar resection sufficient for carcinoid tumors?. Ann Thorac Surg. 2011 Nov. 92 (5):1774-8; discussion 1778-9. [QxMD MEDLINE Link].

31. Taştepe AI, Kurul IC, Demircan S, Liman ST, Kaya S, Cetin G. Long-term survival following bronchotomy for polypoid bronchial carcinoid tumours. Eur J Cardiothorac Surg. 1998 Dec. 14 (6):575-7. [QxMD MEDLINE Link].

32. Lemaitre J, Mansour Z, Kochetkova EA, Koriche C, Ducrocq X, Wihlm JM, et al. Bronchoplastic lobectomy: do early results depend on the underlying pathology? A comparison between typical carcinoids and primary lung cancer. Eur J Cardiothorac Surg. 2006 Jul. 30 (1):168-71. [QxMD MEDLINE Link].

33. Lou F, Sarkaria I, Pietanza C, Travis W, Roh MS, Sica G, et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg. 2013 Oct. 96 (4):1156-1162. [QxMD MEDLINE Link].

34. Bosman FT, Carneiro F, Hruban RH, Theise ND. World Health Organization Classification of Tumours of the Digestive System. Lyon, France: IARC; 2010.

35. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006 Oct. 449 (4):395-401. [QxMD MEDLINE Link]. [Full Text].

36. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007 Oct. 451 (4):757-62. [QxMD MEDLINE Link]. [Full Text].

37. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004.

38. [Guideline] Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015 Aug. 26 (8):1604-20. [QxMD MEDLINE Link]. [Full Text].

39. [Guideline] Öberg K, Hellman P, Ferolla P, Papotti M, ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct. 23 Suppl 7:vii120-3. [QxMD MEDLINE Link]. [Full Text].

40. [Guideline] NCCN Clinical Practice Guidelines in Oncology: neuroendocrine and adrenal tumors. Version 1.2022. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. May 23, 2022; Accessed: July 25, 2022.

41. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.

42. [Guideline] Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jul. 31 (7):844-860. [QxMD MEDLINE Link]. [Full Text].

43. [Guideline] Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Nov. 31 (11):1476-1490. [QxMD MEDLINE Link]. [Full Text].

44. [Guideline] Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012 Jan. 61 (1):6-32. [QxMD MEDLINE Link]. [Full Text].

45. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010 Aug. 39 (6):707-12. [QxMD MEDLINE Link]. [Full Text].

46. [Guideline] Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May. 42 (4):557-77. [QxMD MEDLINE Link]. [Full Text].

47. [Guideline] Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, et al. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. J Thorac Oncol. 2020 Oct. 15 (10):1577-1598. [QxMD MEDLINE Link]. [Full Text].

Mary C Mancini, MD, PhD, MMM

Mary C Mancini, MD, PhD, MMM is a member of the following medical societies: American Association for Thoracic Surgery, American College of Surgeons, American Surgical Association, Phi Beta Kappa, Society of Thoracic Surgeons

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Shreekanth V Karwande, MBBS Chair, Professor, Department of Surgery, Division of Cardiothoracic Surgery, University of Utah School of Medicine and Medical Center

Shreekanth V Karwande, MBBS is a member of the following medical societies: American Association for Thoracic Surgery, American College of Chest Physicians, American College of Surgeons, American Heart Association, Society of Critical Care Medicine, Society of Thoracic Surgeons, Western Thoracic Surgical Association

Disclosure: Nothing to disclose.

Jeffrey C Milliken, MD Former Chief, Division of Cardiothoracic Surgery, University of California at Irvine Medical Center; Clinical Professor, Department of Surgery, University of California, Irvine, School of Medicine; Current Professor Emeritus, University of California

Jeffrey C Milliken, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Thoracic Surgery, American College of Cardiology, American College of Chest Physicians, American College of Surgeons, American Heart Association, American Society for Artificial Internal Organs, California Medical Association, International Society for Heart and Lung Transplantation, Phi Beta Kappa, Society of Thoracic Surgeons, SWOG, Western Surgical Association

Disclosure: Nothing to disclose.

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous author Jane M Eggerstedt, MD, to the development and writing of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article